A5071630168- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Testicular diseases and treatments
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Inflammatory Biomarkers in Disease Prognosis
- Cancer-related Molecular Pathways
- Gastrointestinal Tumor Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Sarcoma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Risks and Factors
- Monoclonal and Polyclonal Antibodies Research
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi
2014-2025
Sağlık Bilimleri Üniversitesi
2020-2025
Haydarpaşa Numune Eğitim ve Araştırma Hastanesi
2025
University of Health Sciences Antigua
2024
Bahçeşehir University
2017
Gazi University
2017
Bülent Ecevit University
2017
Istanbul University
2012-2015
Okmeydanı Eğitim ve Araştırma Hastanesi
2014
Marmara Üniversitesi Eğitim ve Araştırma Hastanesi
2014
Abstract Neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced, high-risk breast cancer. Pathological complete response (pCR) improves survival. Peripheral blood-derived indices reflecting systemic inflammation and nutritional status have long been used as predictive prognostic markers in solid malignancies. This retrospective study investigates whether eight commonly patients receiving NACT affect pCR includes 624 advanced cancer who received NACT. The biomarker...
Background and Objectives: Early-onset breast cancer (EOBC), particularly in patients under 40, presents with distinct biological characteristics worse survival outcomes compared to late-onset cases. Despite intensive treatments, EOBC patients, especially those hormone receptor-positive, HER2-negative (HR+/HER2-) subtypes, show poorer prognosis. CDK4/6 inhibitors, combined endocrine therapy (ET) have become the standard for HR+/HER2- metastatic cancer, yet younger are underrepresented...
Background and Objectives: ROS1 rearrangement is a rare but targetable alteration in non-small-cell lung cancer (NSCLC), occurring 1–2% of cases. Crizotinib, tyrosine kinase inhibitor, has demonstrated efficacy clinical trials, real-world data remain limited. This study evaluates the safety crizotinib ROS1-rearranged NSCLC patients setting. Materials Methods: multicenter, retrospective research included 43 individuals with advanced/metastatic confirmed rearrangements. Patients were treated...
Background and Objectives: CDK4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone receptor-positive HER2 negative (HR(+)/HER2(-)) breast cancer. Despite their efficacy, interstitial lung disease (ILD) remains a rare but potentially fatal adverse effect. This study aims to evaluate incidence clinical characteristics ILD associated with in cancer patients Turkey. Materials Methods: A retrospective multicenter analysis included 464 treated between January 2017 April 2024....
Background/Objectives: Metastatic renal cell carcinoma (mRCC) is a heterogeneous disease requiring precise risk stratification for optimal treatment selection. The International RCC Database Consortium (IMDC) model classifies patients into favorable-, intermediate-, and poor-risk groups; however, emerging evidence suggests that the favorable-risk category encompasses with distinct prognoses. This study aims to evaluate whether subclassifying mRCC "very favorable" "favorable" subgroups...
Background and Objectives: KRAS genes are among the most prominent oncogenes that trigger tumor formation in colorectal cancer (CRC) serve as predictive biomarkers for resistance to anti-EGFR therapies metastatic (mCRC) patients. However, prevalence mutation spectrum of gene family mCRC patients Turkey have not been sufficiently analyzed. This study investigates frequency distribution mutations across different regions examines gender-related variations. Materials Methods: multicenter...
Abstract Background Tumor-infiltrating lymphocytes (TILs) have emerged as predictive biomarkers in HER2-positive breast cancer, correlating with treatment response and survival outcomes. This study evaluates the impact of TIL levels Ki67 suppression on neoadjuvant therapy efficacy this patient population. Materials methods A retrospective analysis 136 cancer patients was conducted. Patients were stratified by levels, clinical outcomes, including expression, pathological complete (pCR),...
Background and Objectives: HER2-positive breast cancer accounts for approximately 20–30% of all cases is associated with aggressive tumor behavior. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate targeting HER2, a standard second-line therapy patients metastatic disease. However, the impact HER2 immunohistochemistry (IHC) expression levels on T-DM1 efficacy remains unclear. Materials Methods: This retrospective study examined 87 who received following trastuzumab-based therapy....
Neoadjuvant chemotherapy (NAC) is extensively employed in breast cancer (BC), primarily for aggressive subtypes like triple-negative and human epidermal growth factor receptor 2 (HER2)-positive BC estrogen receptor-positive (ER+)/HER2- with high-risk features. In ER+/HER2- BC, pathological complete rates are much lower (<10%), while axillary dissection higher. This study focuses on hormone (HR+)/HER2- patients undergoing NAC, examining its impact response (pCR) rates, specific attention...
Background and Objectives: Colorectal cancer (CRC) poses a major global health challenge, with high incidence rates ongoing treatment debates. Adjuvant chemotherapy benefits for high-risk subgroups, particularly stage II disease, remain controversial. This study seeks to clarify this issue by specifically examining the impact of adjuvant on disease-free survival (DFS) overall (OS) in patients diagnosed T4 colon cancer. Materials Methods: retrospective analyzed undergoing radical surgery...
Background and Objectives: This investigation aimed to determine the impacts of concurrent proton pump inhibitors (PPIs) on progression-free survival (PFS) in patients with hormone receptor-positive HER2-negative metastatic breast cancer managed palbociclib or ribociclib as either initial subsequent line therapy option. Materials Methods: In this retrospective study, were classified "concurrent PPIs" if PPIs given for at least two-thirds period, "no no during period therapy. Each patient was...
Background and Objectives: Lung cancer is the leading cause of cancer-related deaths. Spread through air spaces (STAS) an adverse prognostic factor that has become increasingly known in recent years. This study aims to investigate impact STAS presence on overall survival (OS) disease-free (DFS) patients with surgically resected stage IA-IIIA lung identify clinicopathological features associated STAS. Materials Methods: research involved 311 surgery patients. The relationship between...
Prognosis of metastatic gastric cancer is poor and median survival between 3 5 months. Response rates combination chemotherapy with 5-fluorouracil (5-FU) cisplatin in first-line treatment have been found to be 20-25% the English literature. It has demonstrated that adding docetaxel improved time progression overall survival. However, toxicity docetaxel-cisplatin-5-FU protocol were high. In our study we compared efficacy cisplatin-5-FU-folinic acid (CFF) modified (mDCF) regimens...
Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard treatment in locally advanced inoperable non-small cell lung cancer (NSCLC). Our study aimed to compare efficacy toxicities three different regimens delivered concurrently with radiotherapy. We retrospectively reviewed clinical records patients who received PE (cisplatin, 50 mg/m2, on days 1, 8, 29, 36 plus etoposide, 1 5 29 33), PD (docetaxel, 20 day cisplatin, every week), PC (carboplatin,...